AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by Shore Capital in a research report issued to clients and investors on Wednesday, ThisIsMoney.Co.Uk reports.
AZN has been the topic of a number of other research reports. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price target on AstraZeneca and gave the company a “buy” rating in a research report on Tuesday. Goldman Sachs Group set a GBX 5,500 ($71.87) price target on AstraZeneca and gave the company a “sell” rating in a research report on Tuesday, October 1st. Bank of America reaffirmed a “buy” rating and issued a GBX 8,500 ($111.07) price target on shares of AstraZeneca in a research report on Tuesday, October 8th. Jefferies Financial Group increased their price target on AstraZeneca from GBX 6,550 ($85.59) to GBX 6,700 ($87.55) and gave the company a “hold” rating in a research report on Tuesday, October 15th. Finally, Bryan, Garnier & Co reaffirmed a “neutral” rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus target price of GBX 7,137.81 ($93.27).
AZN stock opened at GBX 6,803 ($88.89) on Wednesday. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The firm has a market capitalization of $89.23 billion and a P/E ratio of 39.74. The business’s 50-day moving average is GBX 7,066.01 and its two-hundred day moving average is GBX 6,532.84. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 8,227.88 ($107.51).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Margin
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.